CLVS - CLVS STOCK NEWS

Clovis Oncology, Inc. (NASDAQ:CLVS) has filed a prospectus supplement with the SEC to renew its ATM facility for offering up to $125 million in additional shares of common stock. The sales will be managed by J.P. Morgan Securities LLC and BofA Securities, Inc., through various market methods. Proceeds from the equity offering will support general corporate purposes, including funding development programs and debt repayment. Investors are encouraged to review the prospectus for detailed information regarding risks and the ATM Program.

Clovis Oncology (NASDAQ:CLVS) reported Q2 2021 financial results with global net product revenues of $36.8 million for Rubraca, an 8% decline year-over-year. The company maintained US market share while achieving growth in Europe for ovarian cancer treatments. Clovis anticipates three significant Phase 3 data readouts for Rubraca in the next 6 to 18 months, potentially expanding its market. R&D expenses decreased by 35% to $45.8 million, and SG&A expenses fell by 21% to $32.9 million. Clovis recorded a net loss of $66.4 million but raised $72.5 million through equity offerings.

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its Q2 2021 financial results on August 4, 2021, prior to market opening. A conference call for detailed discussions will take place at 8:30 AM ET on the same day. Investors can access the call via webcast on the Clovis Oncology website, with a 30-day replay available. Clovis focuses on developing and commercializing innovative anti-cancer agents and aims to match treatments with specific cancer populations.

Clovis Oncology, Inc. (NASDAQ: CLVS) has appointed Dr. Ronit Simantov to its Board of Directors. Dr. Simantov, who has extensive experience in oncology research and drug development, will contribute to Clovis' strategic priorities, particularly in advancing the pipeline of Rubraca and targeted radiotherapy candidates like FAP-2286. Her prior roles include chief medical officer at Gamida Cell and vice president at Pfizer, among others. This appointment is expected to strengthen Clovis’ leadership and enhance innovation in its cancer treatment initiatives.

Clovis Oncology (NASDAQ: CLVS) announced a retrospective report on the investigational compound FAP-2286, published in The Journal of Nuclear Medicine. The report highlights a named-patient experience where 11 patients with various metastatic adenocarcinomas received ¹⁷⁷Lu-FAP-2286, demonstrating high tumor uptake and an acceptable toxicity profile. The findings support further clinical investigation. Clovis's Phase 1/2 LuMIERE study aims to evaluate FAP-2286 in advanced solid tumors, targeting FAP-positive lesions. CEO Patrick Mahaffy expressed optimism about advancing FAP-2286's development.

Clovis Oncology (NASDAQ: CLVS) has initiated the first clinical site for its Phase 1/2 LuMIERE study of FAP-2286, a novel peptide-targeted radionuclide therapy, at the O’Neal Comprehensive Cancer Center, UAB. The trial aims to assess the safety and optimal dosage of the therapy, which targets fibroblast activation protein (FAP) prevalent in many solid tumors. This advancement is a significant step toward exploring FAP-2286's potential in treating challenging cancers, with further expansion cohorts planned upon determining the Phase 2 dose.

Clovis Oncology, Inc. (NASDAQ:CLVS) announced the adjournment of its 2021 Annual Meeting of Stockholders concerning Proposal 2, which seeks to increase the authorized shares from 200 million to 250 million. This adjournment allows stockholders more time to vote, with resumption on June 23, 2021. Support for Proposal 2 has surpassed 67.8% of votes cast, but requires over 50% of all shares for approval. All director nominees were elected, and Proposals 3, 4, 5, and 6 received approval. Stockholders are encouraged to vote or modify their votes as needed.

Clovis Oncology (NASDAQ: CLVS) announced four abstracts on Rubraca and lucitanib's clinical studies, to be presented at the 2021 ASCO Annual Meeting from June 4-8, 2021. Key findings include:

• Rubraca showed comparable PFS to chemotherapy in BRCA-mutated ovarian cancer.
• Exceptional benefits from Rubraca noted in 21% of patients in ARIEL3 trial.
• Rubraca's combination with lucitanib demonstrated acceptable safety and 23.5% disease control rate.

Real-world data indicate less than half of eligible ovarian cancer patients receive second-line maintenance therapy.

Clovis Oncology (NASDAQ:CLVS) has filed a prospectus supplement with the SEC to offer and sell shares of its common stock, with a total offering price of up to $75 million through an at-the-market equity offering program. Sales will be managed by J.P. Morgan Securities and BofA Securities, executed under various market conditions. The net proceeds will support corporate purposes, including funding development programs, marketing for Rubraca, debt obligations, and working capital. Investors should consult the prospectus and related documents for more information.